- Report
- January 2024
- 200 Pages
Global
From €4038EUR$4,150USD£3,459GBP
- Report
- January 2021
- 600 Pages
United States
From €2724EUR$2,800USD£2,334GBP
- Report
- October 2022
- 80 Pages
Global
From €5789EUR$5,950USD£4,959GBP
- Report
- June 2019
- 679 Pages
Global
€21406EUR$22,000USD£18,337GBP
- Drug Pipelines
- January 2018
- 9 Pages
Global
From €9730EUR$10,000USD£8,335GBP
- Report
- April 2023
- 129 Pages
Global
€4865EUR$5,000USD£4,168GBP
Eligard is a brand of luteinizing hormone-releasing hormone (LHRH) agonist, a type of drug used to treat breast cancer. It is used to reduce the amount of estrogen in the body, which can slow the growth of certain types of breast cancer. Eligard is administered as an injection, usually once a month, and is typically used in combination with other treatments such as chemotherapy and radiation.
Eligard is one of several drugs used to treat breast cancer, and is part of a larger market of breast cancer drugs. This market includes other LHRH agonists, aromatase inhibitors, and targeted therapies. These drugs are used to treat different stages of breast cancer, from early-stage to advanced-stage.
Companies in the Eligard market include Sanofi, Pfizer, AstraZeneca, Novartis, and Eli Lilly. Show Less Read more
